Retreatment of chronic hepatitis C in previous non-responders and relapsers

• EL-SERAG HB, MASON AC: Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. (1999) 340(10):745-750.
   PubMed Web of Science ®Google Scholar
• LIANG TJ, REHERMANN B, SEEFF LB, HOOFNAGLE JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. (2000) 132(4):296-305.
   PubMedGoogle Scholar
• DI BISCEGLIE AM: Hepatitis C and hepatocellular carcinoma. Hepatology (1997) 26(3 Suppl. 1):S34-S38.
   PubMedGoogle Scholar
• FELD JJ, HOOFNAGLE JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 436(7053):967-972.
   PubMed Web of Science ®Google Scholar
• GALE M Jr: Effector genes of interferon action against hepatitis C virus. Hepatology (2003) 37(5):975-978.
   PubMed Web of Science ®Google Scholar
• HEIM MH: Intracellular signalling and antiviral effects of interferons. Dig. Liver Dis. (2000) 32(3):257-263.
   PubMedGoogle Scholar
• JI X, CHEUNG R, COOPER S et al.: Interferon-α regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology (2003) 37(3):610-621.
   PubMed Web of Science ®Google Scholar
• SEN GC: Viruses and interferons. Annu. Rev. Microbiol. (2001) 55:255-281.
   PubMed Web of Science ®Google Scholar
• TAM RC, PAI B, BARD J et al.: Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. (1999) 30(3):376-382.
   PubMed Web of Science ®Google Scholar
• DIXIT NM, PERELSON AS: The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol. Life Sci. (2006) 63(7-8):832-842.
   PubMed Web of Science ®Google Scholar
• LAU JY, TAM RC, LIANG TJ, HONG Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 35(5):1002-1009.
   PubMed Web of Science ®Google Scholar
• SEEFF LB, HOOFNAGLE JH: National institutes of health consensus development conference: management of hepatitis C: 2002. Hepatology (2002) 36(5 Suppl. 1):S1-S2.
   PubMed Web of Science ®Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY KR et al.: IPeginterferonα-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347(13):975-982.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, SETTE H Jr, MORGAN TR et al.: Peginterferon α-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. (2004) 140(5):346-355.
   PubMed Web of Science ®Google Scholar
• MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958-965.
   PubMed Web of Science ®Google Scholar
• STRADER DB, WRIGHT T, THOMAS DL, SEEFF LB: Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 39(4):1147-1171.
   PubMed Web of Science ®Google Scholar
• EVERSON GT, HOEFS JC, SEEFF LB et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology (2006) 44(6):1675-1684.
   PubMedGoogle Scholar
• CONJEEVARAM HS, FRIED MW, JEFFERS LJ et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 131(2):470-477.
   PubMed Web of Science ®Google Scholar
• JEFFERS LJ, CASSIDY W, HOWELL CD, HU S, REDDY KR: Peginterferon α-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 39(6):1702-1708.
   PubMed Web of Science ®Google Scholar
• MUIR AJ, BORNSTEIN JD, KILLENBERG PG: Peginterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. (2004) 350(22):2265-2271.
   PubMed Web of Science ®Google Scholar
• REDDY KR, HOOFNAGLE JH, TONG MJ et al.: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus interferon study group. Hepatology (1999) 30(3):787-793.
   PubMed Web of Science ®Google Scholar
• HARRISON SA, BRUNT EM, QAZI RA et al.: Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. (2005) 3(6):604-609.
   PubMed Web of Science ®Google Scholar
• PATTON HM, PATEL K, BEHLING C et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. (2004) 40(3):484-490.
   PubMed Web of Science ®Google Scholar
• POYNARD T, RATZIU V, MCHUTCHISON J et al.: Effect of treatment with Peginterferon or interferon α-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 38(1):75-85.
   PubMed Web of Science ®Google Scholar
• D'SOUZA R, SABIN CA, FOSTER GR: Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am. J. Gastroenterol. (2005) 100(7):1509-1515.
   PubMed Web of Science ®Google Scholar
• ROMERO-GOMEZ M, DEL MAR VILORIA M, ANDRADE RJ et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology (2005) 128(3):636-641.
   PubMed Web of Science ®Google Scholar
• MOCHIDA S, OHNISHI K, MATSUO S, KAKIHARA K, FUJIWARA K: Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin. Exp. Res. (1996) 20(9 Suppl.):A371-A377.
   PubMed Web of Science ®Google Scholar
• OHNISHI K, MATSUO S, MATSUTANI K et al.: Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am. J. Gastroenterol. (1996) 91(7):1374-1379.
   PubMed Web of Science ®Google Scholar
• DIAGO M, CASTELLANO G, GARCIA-SAMANIEGO J et al.: Association of pretreatment serum interferon-Γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut (2006) 55(3):374-379.
   PubMed Web of Science ®Google Scholar
• RANDALL G, CHEN L, PANIS M et al.: Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 131(5):1584-1591.
   PubMed Web of Science ®Google Scholar
• CARRAT F, BANI-SADR F, POL S et al.: Pegylated interferon-α-2a vs standard interferon-α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (2004) 292(23):2839-2848.
   PubMed Web of Science ®Google Scholar
• CHUNG RT, ANDERSEN J, VOLBERDING P et al.: Peginterferon-α-2a plus ribavirin versus interferon-α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. (2004) 351(5):451-459.
   PubMed Web of Science ®Google Scholar
• TORRIANI FJ, RODRIGUEZ-TORRES M, ROCKSTROH JK et al.: Peginterferon-α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. (2004) 351(5):438-450.
   PubMed Web of Science ®Google Scholar
• JACOBSON I, BROWN R, FREILICH B et al.: Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology (2005) 42(S1):A749.
   PubMed Web of Science ®Google Scholar
• JEN JF, GLUE P, GUPTA S, ZAMBAS D, HAJIAN G et al.: Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther. Drug Monit. (2000) 22(5):555-565.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG MANNS M, PATEL K et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 123(4):1061-1069.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN M, GHANY M, MORGAN T et al.: Impact of reducing peginterferon-α-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 132(1):103-112.
   PubMedGoogle Scholar
• BARBARO G, DI LORENZO G, BELLONI G et al.: Interferon-α-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon α therapy: a randomized trial. Am. J. Med. (1999) 107(2):112-118.
   PubMedGoogle Scholar
• DAVIS GL, ESTEBAN-MUR R, RUSTGI V et al.: Interferon-α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1998) 339(21):1493-1499.
   PubMed Web of Science ®Google Scholar
• ENRIQUEZ J, GALLEGO A, TORRAS X et al.: Retreatment for 24 vs 48 weeks with interferon-α-2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J. Viral. Hepat. (2000) 7(6):403-408.
   PubMed Web of Science ®Google Scholar
• MARCO VD, ALMASIO P, VACCARO A et al.: Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months. J. Hepatol. (2000) 33(3):456-462.
   PubMedGoogle Scholar
• CHENG SJ, BONIS PA, LAU J, PHAM NQ, WONG JB: Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology (2001) 33(1):231-240.
   PubMedGoogle Scholar
• CUMMINGS KJ, LEE SM, WEST ES et al.: Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA (2001) 285(2):193-199.
   PubMed Web of Science ®Google Scholar
• MIN AD, JONES JL, ESPOSITO S et al.: Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am. J. Gastroenterol. (2001) 96(4):1143-1149.
   PubMedGoogle Scholar
• SAN MIGUEL R, GUILLEN F, CABASES JM, BUTI M: Meta-analysis: combination therapy with interferon-α2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Aliment Pharmacol. Ther. (2002) 16(9):1611-1621.
   PubMedGoogle Scholar
• SHIFFMAN ML, HOFMANN CM, GABBAY J et al.: Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group. Am. J. Gastroenterol. (2000) 95(10):2928-2935.
   PubMedGoogle Scholar
• KRAWITT EL, ASHIKAGA T, GORDON SR et al.: Peginterferon-α-2b and ribavirin for treatment-refractory chronic hepatitis C. J. Hepatol. (2005) 43(2):243-249.
   PubMedGoogle Scholar
• JACOBSON IM, GONZALEZ SA, AHMED F et al.: A randomized trial of peginterferon-α-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol. (2005) 100(11):2453-2462.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN ML, DI BISCEGLIE AM, LINDSAY K et al.: Peginterferon-α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 126(4):1015-1023; discussion 947.
   PubMed Web of Science ®Google Scholar
• SHERMAN M, YOSHIDA EM, DESCHENES M et al.: Peginterferon-α-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 55(11):1631-1638.
   PubMedGoogle Scholar
• POYNARD T, SCHIFF E, TERG R et al.: Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving Peg-Intron/Rebetol (PR) weight based dosing (WBD). J. Hepatol. (2005) 42:40-41.
   Google Scholar
• TALIANI G, GEMIGNANI G, FERRARI C et al.: Pegylated interferon α-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology (2006) 130(4):1098-1106.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-TAPIAS JM, DIAGO M, ESCARTIN P et al.: Peginterferon-α-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology (2006) 131(2):451-460.
   PubMed Web of Science ®Google Scholar
• FERENCI P: Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J. Antimicrob. Chemother. (2004) 53(1):15-18.
   PubMed Web of Science ®Google Scholar
• FERENCI P, FRIED MW, SHIFFMAN ML et al. : Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon-α-2a (40 KD)/ribavirin. J. Hepatol. (2005) 43(3):425-433.
   PubMed Web of Science ®Google Scholar
• JENSEN DM, MORGAN TR, MARCELLIN P et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology (2006) 43(5):54-60.
   PubMedGoogle Scholar
• JENSEN DM, MARCELLIN P: Rationale and design of the REPEAT study: a Phase III, randomized, clinical trial of peginterferon-α-2a (40 kDa) plus ribavirin in non-responders to peginterferon α-2b (12 kDa) plus ribavirin. Eur. J. Gastroenterol. Hepatol. (2005) 17(9):899-904.
   PubMedGoogle Scholar
• MARCELLIN P, TEUBER G, CANVA V et al.: Efficacy of standard-dose and fixed-dose induction peginterferon α-2a (40 kD)(PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon α-2b (12 kD)/ribavirin non-responders: interim analysis of the REPEAT Study. J. Hepatol. (2006) 44(S2):S7.
   Google Scholar
• DIAGO M, ROMERO-GOMEZ M, CRESPO J et al.: Peginterferon α-2A (40 KD) (Pegasys) and ribavirin (Copegus) in patients infected with HCV genotype I who failed to respond to interferon and ribavirin: final results of the Spanish high-dose induction pilot trial. Hepatology (2004) 40:A389 (Abstract).
   Google Scholar
• FRIED M, JENSEN D, RODRIGUEZ-TORRES M et al.: Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon α-2a (40 KD) (PEGASYS®) plus ribavirin (RBV)(COPEGUS®) in patients with “difficult-to-cure” characteristics. Hepatology (2006) 44(S1):A314.
   PubMedGoogle Scholar
• BERG C, GONCALES FL Jr, BERNSTEIN DE et al.: Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-α-2a (40 kDa) and ribavirin. J. Viral. Hepat. (2006) 13(7):435-440.
   PubMed Web of Science ®Google Scholar
• BLATT LM, DAVIS JM, KLEIN SB, TAYLOR MW et al.: The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J. Interferon Cytokine Res. (1996) 16(7):489-499.
   PubMed Web of Science ®Google Scholar
• OZES ON, REITER Z, KLEIN S, BLATT LM, TAYLOR MW: A comparison of interferon-Con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res. (1992) 12(1):55-59.
   PubMedGoogle Scholar
• HEATHCOTE EJ, KEEFFE EB, LEE SS et al.: Re-treatment of chronic hepatitis C with consensus interferon. Hepatology (1998) 27(4):1136-1143.
   PubMed Web of Science ®Google Scholar
• HEATHCOTE EJ, JAMES S, MULLEN KD et al.: Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology (1999) 30(2):562-566.
   PubMedGoogle Scholar
• BOCHER WO, SCHUCHMANN M, LINK R et al.: Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-α therapy. Liver Int. (2006) 26(3):319-325.
   PubMedGoogle Scholar
• CORNBERG M, HADEM J, HERRMANN E et al.: Treatment with daily consensus interferon (Cinterferon) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J. Hepatol. (2006) 44(2):291-301.
   PubMed Web of Science ®Google Scholar
• KAISER S, HASS H, LUTZE B, GREGOR M: Comparison of daily consensus interferon versus peginterferon α-2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C. Gastroenterology (2006) 130(4 Suppl. 2):A784.
   Google Scholar
• GHALIB R, LEVINE C, MOUTI M et al.: 24 week response to consensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior peg interferon plus ribavirin therapy. Gastroenterology (2006) 130(4 Suppl. 2):A845.
   Google Scholar
• ROTHSTEIN K, KOKA R, FERNANDEZ A et al.: Successful treatment with high dose consensus interferon and ribavirin of patients with chronic hepatitis C who are resistant to peg-interferon and ribavirin therapy. Gastroenterology (2006) 130(4 Suppl. 2):A286.
   PubMedGoogle Scholar
• BACON B, REGEV A, GHALIB R et al.: Use of daily interferonα con-1 (Infergen(r), Cinterferon) plus ribavirin (RBV) in patients infected with hepatitis C (HCV) who are nonresponders to previous pegylated interferon plus RBV therapy: 24-week data from the DIRECT trial. Hepatology (2006) 44(S1):A698.
   Google Scholar
• YOSHIDA H, ARAKAWA Y, SATA M et al.: Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 123(2):483-491.
   PubMed Web of Science ®Google Scholar
• NISHIGUCHI S, KUROKI T, NAKATANI S et al.: Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 346(8982):1051-1055.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, SHIRATORI Y, MORIYAMA M et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. (1999) 131(3):174-181.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, TATEISHI R, ARAKAWA Y et al.: Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut (2004) 53(3):425-430.
   PubMedGoogle Scholar
• POYNARD T, MCHUTCHISON J, MANNS M et al.: Impact of pegylated interferon α-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 122(5):1303-1313.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN ML, HOFMANN CM, CONTOS MJ et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 117(5):1164-1172.
   PubMed Web of Science ®Google Scholar
• LEE WM, DIENSTAG JL, LINDSAY KL et al.: Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control. Clin. Trials (2004) 25(5):472-492.
   PubMedGoogle Scholar
• AFDHAL N, FREILICH B, LEVINE R et al.: Colchicine versus Peg-Intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology (2004) 40:A239.
   Google Scholar
• CURRY M, CARDENAS A, AFDHAL NH: Effect of maintenence Peg-Intron therapy on portal hypertension and its complications: results from the COPILOT study. J Hepatology (2005) 42(1 suppl2):40.
   Google Scholar
• DIETERICH DT, WASSERMAN R, BRAU N et al.: Once-weekly epoetin α improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon α. Am. J. Gastroenterol. (2003) 98(11):2491-2499.
   PubMed Web of Science ®Google Scholar
• AFDHAL NH, DIETERICH DT, POCKROS PJ et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 126(5):1302-1311.
   PubMed Web of Science ®Google Scholar
• COLLANTES RS, YOUNOSSI ZM: The use of growth factors to manage the hematologic side effects of peg-interferon α and ribavirin. J. Clin. Gastroenterol. (2005) 39(1 Suppl.):S9-S13.
   Web of Science ®Google Scholar
• O'BRIEN C, GODOFSKY E, RODRIGUEZ-TORRES M et al.: Randomized trial of valopicitabine (NM283), alone or with peg-interferon plus ribavirin (peginterferon/RBV) in hepatitis C patients with previous non-response to peg-interferon/RBV: first interim results. Hepatology (2005) 42(S1):A234.
   Google Scholar
• POCKROS P, O'BRIEN C, GODOFSKY E et al.: Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (peginterferon/RBV) retreatment in hepatitis C patients with prior non-response to peginterferon/RBV: week 24 results. Gastroenterology (2006) 130(4 Suppl. 2):A748.
   Google Scholar
• SARRAZIN C, ROUZIER R, WAGNER F et al.: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 132(4):1270-1278.
   PubMed Web of Science ®Google Scholar
• REESINK HW, ZEUZEM S, WEEGINK CJ et al.: Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 131(4):997-1002.
   PubMed Web of Science ®Google Scholar
• SARRAZIN C, KIEFFER TL, BARTELS D et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 132(5):1767-1777.
   PubMed Web of Science ®Google Scholar
• LIN K, PERNI RB, KWONG AD, LIN C: VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. (2006) 50:1813-1822.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN M, PRICE A, HUBBARD S et al.: Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon α-2b (PEGinterferon), high weight based dose ribavirin (RVN) and epoetin α (EPO) enhances sustained virologic response (SVR). Hepatology (2005) 42(S1):A217.
   Google Scholar

Website

• http://www.who.int/mediacentre/factsheets/fs164/en/ Hepatitis C. 2000, October 2000 [cited 2007 June 8].
   Google Scholar